PPARG and hepatocellular carcinoma: Treatment with rosiglitazone, a PPARγ agonist, determines an increase in endogenous and celecoxib-induced PTEN protein levels in hepatoma cells, which in turn contributes to the inhibition of hepatic cancer stemness and growth through the reduction of AKT activation and CD133 and CD44 expression levels [196].